

Special Issue

Non-human Primate Research in Immune Modulation and Drug Discovery

Message from the Guest Editors

Studies using non-human primates (NHP) are at the origin of major scientific discoveries that have led to improvements in human health over the past years. Due to their close similarity to human physiology and genetics, NHP represent the most valuable animal model for numerous diseases and play a central role in translational research to develop vaccines, drugs, and other interventions.

This Special Issue of *Vaccines* is open to original research manuscripts, short communications, perspectives, or reviews focusing on recent advances in immune modulation and drug discovery using NHP models. The submission of articles covering the following research areas is encouraged:

- Development and characterization of NHP models for immune modulation and drug discovery;
- Experimental characterization of immune interventions in NHP models;
- Proof of concept drug development and immune interventions in NHP models;
- Prophylactic and therapeutic translational research.

Guest Editors

Dr. Caroline Pereira Bittencourt Passaes

Dr. Beatrice Jacquelin

Dr. Anne-Sophie Beignon

Dr. Celina Monteiro Abreu

Deadline for manuscript submissions

closed (31 July 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/49145

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).